Equities analysts forecast that Iovance Biotherapeutics Inc (NASDAQ:IOVA) will post earnings of ($0.27) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings. The highest EPS estimate is ($0.22) and the lowest is ($0.31). Iovance Biotherapeutics reported earnings per share of ($0.32) during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.6%. The business is scheduled to announce its next earnings report on Monday, March 11th.
On average, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.24) per share for the current year, with EPS estimates ranging from ($1.32) to ($0.97). For the next year, analysts expect that the company will report earnings of ($1.23) per share, with EPS estimates ranging from ($1.50) to ($0.93). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Iovance Biotherapeutics.
A number of brokerages have recently weighed in on IOVA. ValuEngine lowered shares of Iovance Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, December 7th. Zacks Investment Research lowered shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 13th. BidaskClub raised shares of Iovance Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, December 7th. Cowen reaffirmed a “buy” rating on shares of Iovance Biotherapeutics in a research report on Tuesday, November 6th. Finally, Robert W. Baird started coverage on shares of Iovance Biotherapeutics in a research report on Wednesday, February 6th. They set an “outperform” rating and a $29.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. Iovance Biotherapeutics presently has a consensus rating of “Buy” and a consensus target price of $24.29.
In related news, Director Merrill A. Mcpeak bought 10,000 shares of the business’s stock in a transaction on Thursday, December 13th. The shares were bought at an average price of $9.63 per share, for a total transaction of $96,300.00. Following the completion of the purchase, the director now directly owns 456,583 shares of the company’s stock, valued at $4,396,894.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Iain D. Dukes bought 12,000 shares of the business’s stock in a transaction on Tuesday, December 18th. The stock was bought at an average price of $8.65 per share, for a total transaction of $103,800.00. Following the purchase, the director now directly owns 12,000 shares of the company’s stock, valued at $103,800. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 2,164,106 shares of company stock valued at $22,150,897. Corporate insiders own 9.90% of the company’s stock.
Hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Iovance Biotherapeutics by 8.9% during the second quarter. BlackRock Inc. now owns 6,296,691 shares of the biotechnology company’s stock worth $80,598,000 after acquiring an additional 512,844 shares during the last quarter. Credit Suisse AG grew its stake in shares of Iovance Biotherapeutics by 51.3% during the third quarter. Credit Suisse AG now owns 1,560,825 shares of the biotechnology company’s stock worth $17,559,000 after acquiring an additional 529,511 shares during the last quarter. NF Trinity Capital Hong Kong Ltd grew its stake in shares of Iovance Biotherapeutics by 83.0% during the fourth quarter. NF Trinity Capital Hong Kong Ltd now owns 228,442 shares of the biotechnology company’s stock worth $2,022,000 after acquiring an additional 103,588 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Iovance Biotherapeutics by 8.1% during the third quarter. Vanguard Group Inc now owns 4,048,782 shares of the biotechnology company’s stock worth $45,550,000 after acquiring an additional 302,649 shares during the last quarter. Finally, Stanley Laman Group Ltd. purchased a new stake in shares of Iovance Biotherapeutics during the third quarter worth about $4,244,000. Institutional investors and hedge funds own 74.30% of the company’s stock.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
See Also: Diversification in Your Portfolio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.